文献速递心力衰竭与心肌病心律失常血脂与心血管预防

CAR-T细胞治疗与美国老年医保受益人心血管结局

Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries.
PubMed 文献 · Eur Heart J · 2026-01-01

本研究基于美国Medicare按服务收费的65岁以上住院CAR-T治疗患者(2018-2023年,共3292例),发现主要不良心血管事件(MACE)发生率为5.8%。治疗前房颤/房扑、心肌病和脑血管病与MACE独立相关;MACE与更高的院内死亡和出院后1年死亡相关。

要点

  • CAR-T治疗老年患者MACE发生率为5.8%,最常见为急性心衰(3.1%)。
  • 治疗前房颤/房扑、心肌病、脑血管病是MACE的独立危险因素。
  • MACE与院内死亡(aOR 16.9)及出院后1年死亡(aHR 1.91)升高相关。

核心结论

  • 在最大的美国老年CAR-T治疗队列中,MACE发生率为5.8%,且与院内和1年死亡率升高相关。

研究设计与样本

  • 回顾性队列研究,纳入2018-2023年接受住院CAR-T治疗的3292例65岁以上Medicare按服务收费受益者,基线特征评估于CAR-T前12个月。

主要发现

  • 3292例中191例(5.8%)发生MACE,最常见为急性心衰(3.1%),其次为缺血性卒中(1.3%)和出血性卒中(1%)。
  • 2021-23年期间,MACE还与免疫效应细胞相关神经毒性综合征及更高级别细胞因子释放综合征相关。

临床怎么用

  • 对拟行CAR-T的老年患者,应评估治疗前房颤/房扑、心肌病和脑血管病等心血管合并症以识别MACE高危者。
  • CAR-T治疗后需监测MACE,因其与院内及1年死亡风险显著升高相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Chimeric antigen receptor T-cell (CAR-T) therapies are cellular immunotherapies that improve survival in patients with relapsed haematologic malignancies. However, their association with major adverse cardiovascular events (MACE) has received limited study, particularly in older adults. This study investigated the incidence of MACE, associated risk factors, and their impact on survival among older patients undergoing CAR-T in the USA. METHODS: Medicare fee-for-service beneficiaries over 65 who received inpatient CAR-T therapy between 2018 and 2023 were included. Baseline characteristics were assessed during the 12 months preceding CAR-T. MACE were defined as a composite of acute heart failure (HF), cardiogenic shock, myocardial infarction, cardiac tamponade, ventricular arrhythmia, complete heart block, or stroke. Multivariable models were adjusted for demographics, malignancy type, and baseline cardiovascular comorbidities. RESULTS: Among 3292 patients receiving CAR-T, 191 (5.8%) had MACE. Most common events were acute HF (3.1%), followed by ischaemic (1.3%) and haemorrhagic stroke (1%). Pre-treatment atrial fibrillation/flutter [adjusted odds ratio (aOR) 1.52 (1.08-2.16)], cardiomyopathy [aOR 2.49 (1.75-3.54)], and cerebrovascular disease [aOR 2.40 (1.30-4.43)] were independently associated with MACE. In 2021-23, MACE were also associated with immune effector cell-associated neurotoxicity syndrome and higher-grade cytokine release syndrome. MACE were associated with higher in-hospital mortality [aOR 16.9 (11.0-26.1)] and 1-year mortality after discharge [adjusted hazard ratio 1.91 (1.46-2.49)]. CONCLUSIONS: In the largest national sample of older adults receiving CAR-T, MACE occurred in 5.8% of patients and were associated with increased in-hospital and 1-year mortality. Further investigation into preventive and mitigating measures is needed.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Zaghlol R, Deych E, Ladin DA, et al. Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries. Eur Heart J. 2026. PMID: 42199067. doi:10.1093/eurheartj/ehag394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。